Status:
UNKNOWN
Study of the IgA Repertoire During IgA Deposition Nephropathy.
Lead Sponsor:
University Hospital, Limoges
Conditions:
Glomerulonephritis, IGA
Eligibility:
All Genders
18+ years
Brief Summary
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective ...
Detailed Description
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective ...
Eligibility Criteria
Inclusion
- Control population:
- person between the ages of 18 and 55 (persons matched to age and sex (75% male) (N-IgA is more common in humans) free from any pathology.
- oAbsence of proteinuria and hematuria on urine sample (search by strip).
- Patients with N-IgA
- 40 patients with N-IgA whose diagnosis was confirmed by renal biopsy. These may be previously known patients who have not received treatment with corticosteroids or immunosuppressants for 12 months or new patients. The incidence of N-IgA is 20 patients per Mh; the number of incident patients with N-IgA is 10-15 per year in the nephrology department. The recruitment of 40 patients over 1 year is feasible.
- Participant's written consent
Exclusion
- Secondary or associated N-IgA (infection, malignant disease, inflammatory bowel disease,
- Rheumatic autoimmune disease or other;
- treatment with corticosteroids or immunosuppressants for less than 12 months.
- person on dialysis
Key Trial Info
Start Date :
November 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04092491
Start Date
November 15 2019
End Date
May 1 2021
Last Update
January 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Néphrologie
Limoges, France, 87042